Thalidomide as a Potent Inhibitor of Neointimal Hyperplasia after Balloon Injury in Rat Carotid Artery

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 24, Issue 5, 2004, Pages 885-891

  Park, Seung Jung ^a,b   Kim, Hyo Soo ^a,b   Yang, Han Mo ^a,b   Park, Kyung Woo ^a,b   Youn, Seock Won ^a   Jeon, Soo In ^a   Kim, Dae Hee ^a,b   Koo, Bon Kwon ^a,b   Chae, In Ho ^a,b   Choi, Dong Joo ^a,b   Oh, Byung Hee ^a,b   Lee, Myoung Mook ^a,b   Park, Young Bae ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

BFGF; Inflammation; Neointima; Thalidomide; TNF

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTERY INTIMA PROLIFERATION; ARTICLE; CAROTID ARTERY INJURY; CONTROLLED STUDY; DRUG EFFICACY; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MACROPHAGE ACTIVATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BALLOON DILATATION; CAROTID ARTERIES; CAROTID STENOSIS; DRUG EVALUATION, PRECLINICAL; FIBROBLAST GROWTH FACTOR 2; HYPERPLASIA; INFLAMMATION; MACROPHAGES; MALE; RATS; RATS, SPRAGUE-DAWLEY; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA; TUNICA INTIMA; VASCULITIS;

EID: 2442588852     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000124924.21961.c3     Document Type: Article

References (36)

1. Topol EJ, Serruys PW. Frontiers in interventional cardiology. Circulation. 1998;98:1802-1820.
2. Welt FG, Rogers C. Inflammation and restenosis in the stent era. Arterioscl Thromb Vasc Biol. 2002;22:1769-1776.
3. Danenberg HD, Welt FG, Walker M 3rd, Seifert P, Toegel GS, Edelman ER. Systemic inflammation induced by lipopolysaccharide increases neointimal formation after balloon and stent injury in rabbits. Circulation. 2002;105:2917-2922.
4. Tanaka H, Sukhova GK, Swanson SJ, Clinton SK, Ganz P, Cybulsky MI, Libby P. Sustained activation of vascular cells and leukocytes in the rabbit aorta after balloon injury. Circulation. 1993;88:1788-1803.
5. Serrano CV Jr., Ramires JA, Venturinelli M, Arie S, D'Amico E, Zweier JL, Pileggi F, da Luz PL. Coronary angioplasty results in leukocyte and platelet activation with adhesion molecules expression: evidence of inflammatory responses in coronary angioplasty. J Am Coll Cardiol. 1997;29:1276-1283.
6. Clausell N, de Lima VC, Molossi S, Liu P, Turley E, Gotlieb AI, Adelman AG, Rabinovitch M. Expression of tumor necrosis factor alpha and accumulation of fibronectin in coronary artery restenotic lesions retrieved by artherectomy. Br Heart J. 1995;73:534-539.
7. Lowe HC, Chesterman CN, Hopkins AP, Juergens CP, Khachigian LM. Acute local release of fibroblast growth factor-2 but not transforming growth factor-beta1 following coronary stenting. Thromb Haemost. 2001;85:574-576.
8. Edelman ER, Nugent MA, Smith LT, Karnovsky MJ. Basic fibroblast growth factor enhances the coupling of intimal hyperplasia and proliferation of vasa vasorum in injured rat arteries. J Clin Invest. 1992;89:465-473.
9. Koch W, Bottiger C, Mehilli J, von Beckerath N, Neumann FJ, Schomig A, Kastrati A. Association of a CD 18 gene polymorphism with a reduced risk of restenosis after coronary stenting. Am J Cardiol. 2001;88:1120-1124.
10. Humphries S, Bauters C, Meirhaeghe A, Luong L, Bertrand M, Amouyel P. The 5A6A polymorphism in the promoter of the stromelysin-1 (MMP3) gene as a risk factor for restenosis. Eur Heart J. 2002;23:721-725.
11. Raje N, Anderson K. Thalidomide - a revival story. N Engl J Med. 1999;341:1606-1609.
12. Bauditz J, Wedel S, Lochs H. Thalidomide reduces tumor necrosis factor example char mapping and interleukin 12 production in patient with chronic active Crohn's disease. Gut. 2002;50:196-200.
13. Bertolini F, Mingrone W, Alietti A, Ferrucci PF, Cocorocchio E, Peccatori F, Cinieri S, Mancuso P, Corsini C, Burlini A, Zucca E, Martinelli G, Cineri S. Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. Ann Oncol. 2001;12:987-990.
14. Gullestad L, Semb AG, Holt E. Effect of thalidomide in patients with chronic heart failure. Am Heart J. 2002;144:847-850.
15. Agoston I, Dibbs ZI, Wang F, Muller G, Zeldis JB, Mann DL, Bozkurt B. Preclinical and Clinical assessment of the safety and potential efficacy of thalidomide in heart failure. J Card Fail. 2002;8:306-314.
16. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci. 1994;91:4082-4085.
17. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med. 1991;173:699-703.
18. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor example char mapping by enhancing mRNA degradation. J Exp Med. 1993;177:1675-1680.
19. Wainwright CL, Miller AM, Wadsworth RM. Inflammation as a key event in the development of neointima following vascular balloon injury. Clin Exp Pharmacol Physiol. 2001;28:891-895.
20. Tanaka H, Sukhova G, Schwartz D, Libby P. Proliferating arterial smooth muscle cells after balloon injury express TNF-alpha but not interleukin-1 or basic fibroblastic growth factor. Arterioscl Thromb Vasc Biol. 1996;16:12-18.
21. Javed Q, Swanson N, Vohra H, Thurston H, Gershlick AH. Tumor necrosis factor-alpha antibody eluting stents reduce vascular smooth muscle cell proliferation in saphenous vein organ culture. Exp Mol Pathol. 2002;73:104-111.
22. Mori E, Komori K, Yamaoka T, Tanii M, Kataoka C, Takeshita A, Usui M, Egashira K, Sugimachi K. Essential role of monocyte chemoattractant protein-1 in development of restenotic changes (neointimal hyperplasia and constrictive remodeling) after balloon angioplasty in hypercholesterolemic rabbits. Circulation. 2002;105:2905-2910.
23. Bishop GG, McPherson JA, Sanders JM, Hesselbacher SE, Feldman MJ, McNamara CA, Gimple LW, Powers ER, Mousa SA, Sarembock IJ. Selective example char mapping alpha v beta 3-receptor blockade reduces macrophage infiltration and restenosis after balloon angioplasty in the atherosclerotic rabbit. Circulation. 2001;103:1906-1911.
24. Zhou Z, Lauer MA, Wang K, Forudi F, Zhou X, Song X, Solowski N, Kapadia SR, Nakada MT, Topol EJ, Lincoff AM. Effect of anti-tumor necrosis factor-alpha example char mapping polyclonal antibody on restenosis after balloon angioplasty in a rabbit atherosclerotic model. Atherosclerosis. 2002;161:153-159.
25. Lindner V, Reidy MA. Expression of basic fibroblast growth factor and its receptor by smooth muscle cells and endothelium in injured rat arteries. An en face study. Circ Res. 1993;73:589-595.
26. Bouche G, Gas N, Prats H, Baldin V, Tauber JP, Teissie J, Amalric F. Basic fibroblast growth factor enters the nucleolus and stimulate the transcription of ribosomal genes in ABAE cells undergoing G0 example char mapping G1 transition. Proc Natl Acad Sci. 1987;84:6770-6774.
27. Hawker JR Jr., Granger HJ. Internalized basic fibroblast growth factor translocates to nuclei of venular endothelial cells. Am J Physiol. 1992;262(5Pt2):H1525-H1537.
28. Bailly K, Soulet F, Leroy D, Amalric F, Bouche G. Uncoupling of cell proliferation and differentiation activities of basic fibroblast growth factor. FASEB J. 2000;14(2):333-344.
29. Cuevas P, Gonzalez AM, Carceller F, Baird A. Vascular response to basic fibroblast growth factor when infused into the normal adventitia or into the injured media of the rat carotid artery. Circ Res. 1991;69:360-369.
30. Lindner V, Reidy MA. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci. 1991;88:3739-3743.
31. Lienenluke B, Stojanovic T, Fiebig T, Fayyazi A, Germann T, Hecker M. Thalidomide impairment of trinitrobenzene sulphonic acid-induced colitis in the rat - role of endothelial cell-leukocyte interaction. Br J Pharmacol. 2001;133:1414-1423.
32. Finnell RH, Waes JG, Eudy JD, Rosenquist TH. Molecular basis of environmentally induced birth defects. Annu Rev Pharmacol Toxicol. 2002;42:181-208.
33. Settles B, Stevenson A, Wilson K, Mack C, Ezell T, Davis MF, Taylor LD. Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-alpha agent thalidomide. Cell Mol Biol. 2001;47:1105-1114.
34. Breuss JM, Cejna M, Bergmeister H, Kadl A, Baumgartl G, Steurer S, Xu Z, Koshelnick Y, Lipp J, De Martin R, Losert U, Lammer J, Binder BR. Activation of nuclear factor kappa-B significantly contributes to lumen loss in a rabbit iliac artery balloon angioplasty mode. Circulation. 2002;105:633-638.
35. Meiners S, Laule M, Rother W, Guenther C, Prauka I, Muschick P, Baumann G, Kloetzel PM, Stangl K. Ubiquitin-proteasome pathway as a new target for the prevention of restenosis. Circulation. 2002;105:483-489.
36. Majumdar S, Lamothe B, Aggarwal BB. Thalidomide suppresses NF-kB activation induced by TNF-&[alpha] example char mapping and H2O2, but not that activated by ceramide, lipopolysaccharide, or phorbol ester. J Immunol. 2002;168:2644-2651.